- 12-month Phase 2 FIGHT DMD trial met clinical endpoint with 5.4% absolute LVEF improvement (p=0.002) in high-dose group vs matched controls.
- Observed reductions in key cardiac damage markers (NT-proBNP and cardiac troponin I).
- Positive pipeline advancement for lead candidate in rare disease indication.
?? Positive AI Sentiment (+6.8 / 10)